LAWRENCEVILLE, N.J. , Feb. 21, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that on February 19, 2019 , the Compensation Committee of the Company's Board of Directors approved the grant of (i) inducement stock options (the

LAWRENCEVILLE, N.J. , Jan. 24, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that Jeffrey Church , Celsion’s Executive Vice President and Chief Financial Officer, will present at NobleConXV - Noble Capital Markets’ 15 th Annual

Publication Highlights Phase I Data Supporting Safety and Feasibility of Treatment with ThermoDox ® and Non-Invasive, Focused Ultrasound University of Oxford’s Findings Provide Additional Independent Evidence of ThermoDox’s Unique and Highly Effective Anti-Cancer Mechanism LAWRENCEVILLE, N.J , Jan.

Data to be Highlighted During Oral Session on March 2, 2019 LAWRENCEVILLE, N.J. , Jan. 15, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that data from a Phase I study of GEN-1, its DNA-based immunotherapy for the localized

Current Combined, Blinded Progression-Free Survival (PFS) Rate for Both Treatment Arms Reaches 21.2 Months Compared to 19.8 Months for the Intent-To-Treat (ITT) Population in the HEAT Study Post-Hoc Analysis Subgroup Current Combined, Blinded Overall Survival (OS) Rate for Both Treat Arms is

Non-Dilutive Funding Strengthens Balance Sheet Proceeds Equate to More Than $0.55 Per Share LAWRENCEVILLE, N.J. , Dec. 03, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced it has received approval from the New Jersey Economic

ThermoDox® Phase III OPTIMA Study Fully Enrolled in August; First Pre-Planned Efficacy Analysis Expected in Mid-2019 GEN-1 Phase I/II OVATION 2 Study Enrolling Patients; First Look at Phase I Data Expected in First Quarter 2019 Company to Hold Conference Call on Thursday, November 15, 2018 at 11:00

LAWRENCEVILLE, N.J , Nov. 08, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the quarter ended September 30, 2018 and provide an update on its development programs for ThermoDox®, its

  Single Arm Study Demonstrated a Median Progression-Free Survival (PFS) of 24.3 Months for Patients Treated per Protocol;  Patients in the Intent-to-Treat Population had a Median PFS of 17.1 months versus Historical Median PFS of 12 Months All Patients Treated at the Highest Dose Cohort Achieved

  Analysis in peer-reviewed journal, Future Oncology, outlines the ability of GEN-1, a non-viral nanoparticle delivery system, to support persistent local production of IL-12 LAWRENCEVILLE, N.J , Oct. 22, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development